HomeComparePHAS vs VIG

PHAS vs VIG: Dividend Comparison 2026

PHAS yields 2853.07% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHAS wins by $281872346867.01M in total portfolio value
10 years
PHAS
PHAS
● Live price
2853.07%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$281872346867.04M
Annual income
$263,691,193,706,389,300.00
Full PHAS calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — PHAS vs VIG

📍 PHAS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHASVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHAS + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PHAS pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHAS
Annual income on $10K today (after 15% tax)
$242,510.70/yr
After 10yr DRIP, annual income (after tax)
$224,137,514,650,430,900.00/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, PHAS beats the other by $224,137,514,650,430,750.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHAS + VIG for your $10,000?

PHAS: 50%VIG: 50%
100% VIG50/50100% PHAS
Portfolio after 10yr
$140936173433.54M
Annual income
$131,845,596,853,194,750.00/yr
Blended yield
93.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PHAS right now

PHAS
Analyst Ratings
3
Buy
3
Hold
Consensus: Buy
VIG
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHAS buys
0
VIG buys
0
No recent congressional trades found for PHAS or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHASVIG
Forward yield2853.07%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$281872346867.04M$32.4K
Annual income after 10y$263,691,193,706,389,300.00$179.15
Total dividends collected$280611873155.80M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: PHAS vs VIG ($10,000, DRIP)

YearPHAS PortfolioPHAS Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$296,007$285,306.70$11,304$163.92+$284.7KPHAS
2$8,209,503$7,892,775.47$12,759$166.33+$8.20MPHAS
3$213,363,270$204,579,102.60$14,382$168.52+$213.35MPHAS
4$5,197,428,076$4,969,129,376.72$16,192$170.52+$5197.41MPHAS
5$118,688,009,645$113,126,761,603.35$18,210$172.34+$118687.99MPHAS
6$2,541,344,545,416$2,414,348,375,096.37$20,460$173.98+$2541344.52MPHAS
7$51,033,223,710,004$48,313,985,046,408.66$22,968$175.48+$51033223.69MPHAS
8$961,336,701,807,468$906,731,152,437,763.20$25,763$176.83+$961336701.78MPHAS
9$16,991,731,925,840,448$15,963,101,654,906,456.00$28,878$178.05+$16991731925.81MPHAS
10$281,872,346,867,038,600$263,691,193,706,389,300.00$32,350$179.15+$281872346867.01MPHAS

PHAS vs VIG: Complete Analysis 2026

PHASStock

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full PHAS Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this PHAS vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHAS vs SCHDPHAS vs JEPIPHAS vs OPHAS vs KOPHAS vs MAINPHAS vs DGROPHAS vs NOBLPHAS vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.